佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月27日南向资金增持21.66万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有5天，累计净增持447.6万股。近20个交易日中，获南向资金增持的有11天，累计净增持740.1万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7592.1万股，占公司已发行普通股的5.75%。 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，2月13日南向资金增持164.94万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持46.74万股。近20个交易日中，获南向资金增持的有11天，累计净增持801.6万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7309.44万股，占公司已发行普通股的5.54%。 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月12日南向资金减持147.48万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持154.56万股。近20个交易日中，获南向资金增持的有10天，累计净增持537.42 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7144.5万股，占公司已发行普通股的5.41%。 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月10日南向资金减持32.7万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有4天，累计净减持6.42万股。近20个交易日中，获南向资金增持的有11天，累计净增持730.98万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7447.74万股，占公司已发行普通股的5.64%。 ...

| 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-09 | 7480.44万 | 217.74万 | 3.00% | | 2026-02-06 | 7262.70万 | -36.36万 | -0.50% | | 2026-02-05 | 7299.06万 | -70.50万 | -0.96% | | 2026-02-04 | 7369.56万 | -84.60万 | -1.13% | | 2026-02-03 | 7454.16万 | 304.38万 | 4.26% | 证券之星消息，2月9日南向资金增持217.74万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持330.66万股。近20个交易日中，获南向资金增持的有11天，累计净增持716.04 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7480.44万股，占公司已发行普通股的5.66%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，2月5日南向资金减持70.5万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金增 持的有1天，累计净增持126.48万股。近20个交易日中，获南向资金增持的有12天，累计净增持759.36万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7299.06万股，占公司已发行普通股的5.53%。 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，1月28日南向资金增持22.02万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持320.94万股。近20个交易日中，获南向资金增持的有14天，累计净增持882.42 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7170.54万股，占公司已发行普通股的5.42%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core point of the article is that southbound funds have increased their holdings in Baize Medical (02609.HK) by 132,600 shares on November 21, 2025, with a total net increase of 1,084,000 shares over the past 20 trading days [1][2] - As of now, southbound funds hold a total of 63,736,800 shares of Baize Medical, accounting for 4.82% of the company's total issued ordinary shares [1][2] - The company operates primarily in the oncology medical services sector, providing a full cycle of medical services including screening, diagnosis, treatment, and rehabilitation [2] Group 2 - The trading data shows fluctuations in shareholding over the past few days, with a net increase of 10,920 shares over the last five trading days [2] - The company is involved in various aspects of oncology care, including cancer diagnosis, treatment, rehabilitation, and palliative care, as well as early cancer screening and health management services [2]

Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 800.16 million shares on September 19, 2025, marking a significant increase in investment interest [1] - Over the past five trading days, Baize Medical has seen a cumulative net increase of 61.66 million shares held by southbound funds, indicating strong demand [1] - As of now, southbound funds hold a total of 64.40 million shares of Baize Medical, representing 4.88% of the company's total issued ordinary shares [1] Trading Data Summary - On September 19, 2025, total shares held reached 64.40 million, with a change of 800.16 million shares, reflecting a 14.19% increase [2] - On September 18, 2025, total shares held were 56.40 million, with a change of 20.24 million shares, showing a 55.96% increase [2] - On September 17, 2025, total shares held were 36.16 million, with a change of 16.90 million shares, indicating an 87.75% increase [2] - On September 16, 2025, total shares held were 19.26 million, with a change of 16.29 million shares, representing a 547.44% increase [2] - On September 15, 2025, total shares held were 2.97 million, with a change of 0.24 million shares, reflecting an 8.66% increase [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology care [2] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [2] - Baize Medical's operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2] - The company primarily operates in the Chinese market, providing services such as cancer diagnosis, treatment, rehabilitation, and end-of-life care [2]

Core Viewpoint - Baize Medical Group Limited is planning to go public on the Hong Kong Stock Exchange, with a global offering of 133 million shares and an expected fundraising amount between HKD 562 million and HKD 898 million [1][3]. Company Overview - Baize Medical was established in July 2017 and is primarily engaged in investment and provision of medical services related to oncology, operating 8 hospitals across various provinces in China [5][6]. - The company has a registered capital of RMB 1.234 billion and is fully controlled by Beijing Baibai Medical Management [3][5]. Financial Performance - The revenue for Baize Medical for the years 2022, 2023, and 2024 was approximately RMB 803 million, RMB 1.072 billion, and RMB 1.189 billion, respectively, showing a growth trend despite ongoing losses [6][7]. - The net losses for the same years were RMB 75.5 million, RMB 24.4 million, and RMB 3.6 million, indicating a narrowing loss margin [6][8]. - Adjusted net profits (non-IFRS) for the years were approximately -RMB 75.3 million, -RMB 9.6 million, and RMB 12.5 million, with adjusted EBITDA of RMB 35.3 million, RMB 122.3 million, and RMB 135.6 million [8]. Business Operations - The company operates 6 for-profit hospitals and manages 2 non-profit hospitals, focusing on cancer-related medical services, including diagnosis, treatment, rehabilitation, and palliative care [5][6]. - As of December 31, 2024, Baize Medical's hospitals employed 1,119 practicing physicians and had a total of 2,829 medical professionals providing various oncology services [9][10].